Literature DB >> 20559788

Reduced Walker 256 carcinosarcoma growth in vasopressin-deficient Brattleboro rats.

Igor I Khegay1, Nelli A Popova, Ludmila N Ivanova.   

Abstract

The growth pattern of carcinosarcoma Walker 256 was studied in rats with different levels of vasopressin in the blood. The Brattleboro rats are unable to synthesize vasopressin in a consequence of deletion in the coding gene. Hybrids from crossbreeding of the mutant Brattleboro and normal WAG rats inherit the one intact vasopressin gene and hold nearly normal hormone level. It was found that non-strain-specific carcinosarcoma Walker 256 intensively grows in WAG rats and their offsprings from crossbreeding with Brattleboro rats, and tumor development is equally terminated in them by death. Carcinosarcoma grows less intensely in Brattleboro rats; the tumor nodes increased only within the first 2 weeks, after which, the tumor began to decrease and eventually disappeared. Infusion of exogenous vasopressin to Brattleboro rats intensifies a tumor growth in the first 2 weeks after the inoculation of Walker 256 cells; however, it does not prevent a following regression and resorption of tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20559788     DOI: 10.1007/s13277-010-0070-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  17 in total

1.  Lack of vasopressin-independent upregulation of AQP-2 gene expression in homozygous Brattleboro rats.

Authors:  T Saito; S Ishikawa; S Sasaki; M Higashiyama; S Nagasaka; N Fujita; K Fushimi; F Marumo
Journal:  Am J Physiol       Date:  1999-08

2.  Immune system in vasopressin-deficient rats during ontogeny.

Authors:  I I Khegai; M A Gulyaeva; N A Popova; L A Zakharova; L N Ivanova
Journal:  Bull Exp Biol Med       Date:  2003-11       Impact factor: 0.804

Review 3.  Wilms tumor and the WT1 gene.

Authors:  S B Lee; D A Haber
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

4.  The neuroendocrine thymus. Abundant occurrence of oxytocin-, vasopressin-, and neurophysin-like peptides in epithelial cells.

Authors:  U M Moll; B L Lane; F Robert; V Geenen; J J Legros
Journal:  Histochemistry       Date:  1988

5.  cDNA array identification of genes regulated in rat renal medulla in response to vasopressin infusion.

Authors:  Heddwen L Brooks; Shana Ageloff; Tae-Hwan Kwon; William Brandt; James M Terris; Akhil Seth; Luis Michea; Soren Nielsen; Robert Fenton; Mark A Knepper
Journal:  Am J Physiol Renal Physiol       Date:  2002-09-11

6.  Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin deficient Brattleboro rats.

Authors:  Dóra Zelena; Anna Földes; Zsuzsa Mergl; István Barna; Krisztina J Kovács; Gábor B Makara
Journal:  Brain Res Bull       Date:  2004-07-15       Impact factor: 4.077

7.  Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells.

Authors:  S Hashemi; D S Palmer; M T Aye; P R Ganz
Journal:  J Cell Physiol       Date:  1993-03       Impact factor: 6.384

8.  Vasopressin receptor subtype 2 activation increases cell proliferation in the renal medulla of AQP1 null mice.

Authors:  Qi Cai; Matthew R McReynolds; Maggie Keck; Kevin A Greer; James B Hoying; Heddwen L Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2007-10-03

Review 9.  Stress, NK cells, and cancer: Still a promissory note.

Authors:  Shamgar Ben-Eliyahu; Gayle G Page; Steven J Schleifer
Journal:  Brain Behav Immun       Date:  2007-07-26       Impact factor: 7.217

10.  Vasopressin replacement of interleukin 2 requirement in gamma interferon production: lymphokine activity of a neuroendocrine hormone.

Authors:  H M Johnson; W L Farrar; B A Torres
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

View more
  1 in total

1.  Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans.

Authors:  Laine M Heidman; Nahuel Peinetti; Valeria A Copello; Kerry L Burnstein
Journal:  Mol Cancer Res       Date:  2022-08-05       Impact factor: 6.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.